<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In a Danish multicentre trial we compared the relapse preventing effects of olsalazine and sulphasalazine in patients with <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> over a 12 month treatment period </plain></SENT>
<SENT sid="1" pm="."><plain>Two hundred and twenty seven patients (118 men) with at least two previous attacks of <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> were randomly allocated according to a prearranged treatment schedule to olsalazine 500 mg bd or sulphasalazine 1 g bd in a double blind, double dummy fashion </plain></SENT>
<SENT sid="2" pm="."><plain>One hundred and ninety seven patients completed the trial </plain></SENT>
<SENT sid="3" pm="."><plain>The relapse rate after 12 month in the olsalazine group was 46.9% v 42.4% in the sulphasalazine group with a 95% confidence interval for the difference in proportions of -9% to 18% </plain></SENT>
<SENT sid="4" pm="."><plain>Seven per cent of the patients were withdrawn from the trial because of adverse drug reactions and these were equally distributed between the two groups </plain></SENT>
</text></document>